NLRX1 and ulcerative colitis: In addition, NX‐13 activation of NLRX1 also showed resistance to oxidative stress and inflammation in human primary cells from ulcerative colitis patients, therefore becoming a promising NLRX1 agonist for treating IBD [59, 60, 61].